Phase I/II Study of Oncolytic Herpes Simplex Virus NV1020 in Patients with Extensively Pretreated Refractory Colorectal Cancer Metastatic to the Liver
2010
Geevarghese et al. report results from a phase I/II multicenter study evaluating the safety, pharmacokinetics, and antitumor effects of repeated doses of NV1020, a genetically engineered oncolytic herpes simplex virus, in patients with advanced metastatic colorectal cancer (mCRC). The authors reveal that NV1020 stabilizes liver metastases with minimal toxicity in mCRC and leads to a one-year survival rate of 47.2%.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
44
References
93
Citations
NaN
KQI